Abstract: In some embodiments, a system may include a first wearable harness worn, during use, on a torso of a subject. The system may include a second wearable harness worn, during use, on a torso of a subject on an outer surface of the first wearable harness. The system may include a plurality of engines which when activated apply an oscillation force to at least one treatment area. At least one of the plurality of engines may be releasably couplable to the first wearable harness using a positioning system such that the oscillation force is applied to the treatment areas. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject at least adjacent the treatment area. The second wearable harness, when activated, may provide a compressive force to at least some of the activated plurality of engines positioned above the treatment area.

Abstract: In some embodiments, a system may include an inner wearable harness including a flexible vest. The system may include at least one engine which when activated apply an oscillation force. The at least one engine is positioned after the vest has been positioned on the subject on different areas of the inner wearable harness to allow selective placement of engines on and/or adjacent areas of the subject's chest such that the oscillation force is applied to at least one treatment area. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject substantially adjacent the treatment area. The system may include a flexible and elastic outer harness worn, during use, on a torso of a subject which when activated provides a compressive force to adjust the oscillation force applied by at least some of the at least one engine to the treatment area.

Abstract: In some embodiments, a system may include an inner wearable harness worn, during use, on a torso of a subject. The system may include a plurality of engines which when activated apply an oscillation force. The system may include a positioning system which allows positioning at least one of the plurality of engines on the inner wearable system such that the oscillation force is applied to at least one treatment area of the subject. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject substantially adjacent the treatment area. The system may include an outer harness worn, during use, on a torso of a subject. The outer wearable harness, when activated, adjusts the oscillation force applied by at least some of the activated plurality of engines to the treatment area.

Abstract: In some embodiments, a system and/or method may include an inner wearable harness worn, during use, on a torso of a subject which includes a flexible vest. The system may include a plurality of engines, each of which are contained in a flexible container, which when activated apply an oscillation force. The system may include a positioning system which allows positioning the flexible container such that the oscillation force is applied to at least one treatment area of the subject. The oscillation force may mobilize, during use, at least some secretions in an airway within the subject substantially adjacent the treatment area. The system may include an outer harness worn, during use, on a torso of a subject. The outer wearable harness, when activated, adjusts the oscillation force applied by at least some of the activated plurality of engines to the treatment area by providing a compressive force.

Abstract: In some embodiments, a kit may include systems allowing for clearing a biological airway. The kit may include an inner wearable system worn, during use, on a torso of a subject. The kit may include a plurality of engines which when activated apply an oscillation force to at least one treatment area of the subject. At least one of the plurality of engines may be releasably couplable to the inner wearable system. The oscillation force may be applied to at least one of the treatment areas of the subject such that the oscillation force mobilizes, during use, at least some secretions in an airway within the subject at least adjacent the treatment area. The kit may include an outer wearable system worn, during use, on a torso of a subject which when activated, adjusts the oscillation force. The kit may include one or more batteries and/or a control unit.

Abstract: In some embodiments, a method may include clearing a biological airway. The method may include positioning an inner wearable harness on a torso of a subject. The method may include selectively positioning at least some of a plurality of engines on and/or adjacent at least one treatment area. At least one of the plurality of engines may be releasably couplable to the inner wearable harness. The method may include positioning an outer wearable harness on a torso of a subject. The method may include applying an oscillation force to at least one of the treatment areas using at least some of the plurality of engines. The method may include adjusting the applied oscillation force to the treatment area by activating the outer wearable harness. The method may include mobilizing at least some secretions in an airway within the subject substantially adjacent the at least one treatment area.

Abstract: The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof.

Abstract: The present invention provides compounds having the formula: wherein R1 is selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof.

Abstract: Healthcare service providers and others may send claims for payment requesting remittance from insurance companies or patients. Such payments may be remitted through paper or electronic transactions. A financial institution may receive the payment and associated information and process the remittance depending on the remittance source and type. In addition, the institution may generate a single bill generated at a regular interval for the healthcare service provider for the services. The amount of the bill may be based on the volume of remittances.

Abstract: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12; R9 is selected from H —NR13C(O)R14 and —C(O)NR10R11; R12 is selected from H, C1-C6 alkyl and C3-C6 cycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

Abstract: The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C1-C6 alkyl, aryl, heteroaryl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, C2-C6 alkyl-O—C1-C6 alkyl, C1-C6 haloalkyl, hydroxy C2-C6 alkyl, —C(O)R9 and —SO2R9, or R7 and R8 combine to form (III), (IV); W is selected from CR1O and CR15, R1O is selected from H, halo, —C(O)NR13R14, C1-C6 alkyl, aryl, heteroaryl, C1-C6 alkylaryl, C1-C6 alkylheteroaryl, C1-C6 alkyl-O—C1-C6 alkyl and hydroxy C1-C6 alkyl; Het is a N-linked 5-membered heteroaryl ring optionally substituted with 1-3 substituents selected from methoxy, Cl, F, CH3, CF3, aryl, heteroaryl, C1-C4 alkylaryl or C1-C4 alkylheteroaryl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

Abstract: The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C1-C6 alkyl, C1-C6 fluoroalkyl, and —OR12, R9 is selected from H and —C(O)NR1OR1 1, R12 is selected from H, C1-C6 alkyl and C3-C6 cycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

Abstract: A multi-electrode system comprises a fiber support configured to hold at least one optical fiber and a set of electrodes disposed about the at least one optical fiber and configured to generate arcs between adjacent electrodes to generate a substantially uniform heated field to a circumferential outer surface of the at least one optical fiber. The electrodes can be disposed in at least a partial vacuum.

Abstract: A thermal management device for a circuit substrate having at least a first heat generating component and at least a second heat generating component, the thermal management device includes a first thermal spreader and a second thermal spreader. The second thermal spreader is mountable to the circuit substrate to thermally couple with the second heat generating component. Additionally, the second thermal spreader is adapted to couple to the first thermal spreader to thermally couple the first thermal spreader to the first heat generating component when the second thermal spreader is mounted to the circuit substrate. The thermal management device also includes a bias device that is coupled to the first thermal spreader and the second thermal spreader and is adapted to maintain the thermal coupling between the first thermal spreader and the first heat generating component when the second thermal spreader is mounted to the circuit substrate.

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

Abstract: A multi-electrode system comprises a fiber support configured to hold at least one optical fiber and a set of electrodes disposed about the at least one optical fiber and configured to generate arcs between adjacent electrodes to generate a substantially uniform heated field to a circumferential outer surface of the at least one optical fiber. The electrodes can be disposed in at least a partial vacuum.

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Abstract: This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I).

Abstract: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

Abstract: A device to thermally couple a thermal management apparatus to at least one heat generating component of a circuit substrate includes at least a first portion that is adapted to couple to the thermal management apparatus, and at least a second portion that is adapted to couple to the thermal management apparatus. The first portion and the second portion may be symmetrically arranged relative to each other. The first portion and the second portion are adapted to thermally couple the thermal management apparatus to the heat generating component with a first spring bias. The first portion and the second portion are further adapted to maintain the thermal management apparatus thermally coupled to the heat generating component with a second spring bias.